Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1621con

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | DEC 01 | ChemPort single article sales feature unavailable |
| NEWS 3 | JUN 01 | CAS REGISTRY Source of Registration (SR) searching enhanced on STN |
| NEWS 4 | JUN 26 | NUTRACEUT and PHARMAML no longer updated |
| NEWS 5 | JUN 29 | IMSCOPROFILE now reloaded monthly |
| NEWS 6 | JUN 29 | EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields |
| NEWS 7 | JUL 09 | PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields |
| NEWS 8 | JUL 14 | USGENE enhances coverage of patent sequence location (PSL) data |
| NEWS 9 | JUL 27 | CA/CAplus enhanced with new citing references |
| NEWS 10 | JUL 16 | GBFULL adds patent backfile data to 1855 |
| NEWS 11 | JUL 21 | USGENE adds bibliographic and sequence information |
| NEWS 12 | JUL 28 | EPFULL adds first-page images and applicant-cited references |
| NEWS 13 | JUL 28 | INPADOCDB and INPAFAMDB add Russian legal status data |
| NEWS 14 | AUG 08 | Improve STN by completing a survey and be entered to win a gift card |
| NEWS 15 | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes |
| NEWS 16 | AUG 17 | CAS REGISTRY, the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone |
| NEWS 17 | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field |

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

| | |
|---|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.



* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:18:38 ON 20 AUG 2009

=> FILE REG

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.22 | 0.22 |

FILE 'REGISTRY' ENTERED AT 16:18:51 ON 20 AUG 2009


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2009 HIGHEST RN 1174705-31-7
DICTIONARY FILE UPDATES: 19 AUG 2009 HIGHEST RN 1174705-31-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\NO22.str



chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 31 32 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-18 2-25 3-19 4-26 5-13 6-24 7-21 8-14 9-22 10-23 11-17 12-20 13-14
13-16 14-15 17-27 18-32 19-31 27-29 27-28 28-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-18 3-19 11-17 17-27 27-29
exact bonds :
2-25 4-26 5-13 6-24 7-21 8-14 9-22 10-23 12-20 13-14 13-16 14-15 18-32
19-31 27-28 28-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:Cy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 31:CLASS 32:CLASS 33:CLASS

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> S L1 FULL
FULL SEARCH INITIATED 16:19:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 447 TO ITERATE

100.0% PROCESSED 447 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

L2 17 SEA SSS FUL L1

=> FILE CAPLUS

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 186.36 | 186.58 |

FILE 'CAPLUS' ENTERED AT 16:20:06 ON 20 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 20 Aug 2009 VOL 151 ISS 8
FILE LAST UPDATED: 19 Aug 2009 (20090819/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> S L2
L3 2 L2

=> D L2 IBIB ABS HITSTR 1-2
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:Y

'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties
PPROP - Table of predicted properties
PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):END

=> D L3 IBIB ABS HITSTR 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1530346 CAPLUS
DOCUMENT NUMBER: 150:77699
TITLE: Compositions and methods of use for treating or preventing lipid related disorders
INVENTOR(S): Currie, Mark; Talley, John; Cali, Brian
PATENT ASSIGNEE(S): Ironwood Pharmaceuticals, Inc, USA
SOURCE: PCT Int. Appl., 197pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2008157537 | A2 | 20081224 | WO 2008-US67204 | | 20080617 |
| WO 2008157537 | A3 | 20090402 | | | |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| US 20090054450 | A1 | 20090226 | US 2008-140637 | | 20080617 |
| PRIORITY APPLN. INFO.: | | | US 2007-944934P | P | 20070619 |
| | | | US 2008-23744P | P | 20080125 |
| | | | US 2008-30778P | P | 20080222 |

OTHER SOURCE(S): MARPAT 150:77699
GI



I



II



III

AB Disclosed herein are compds. of formula I and II and their compns. and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compns. alone or in combination with one or more lipid altering agents and/or PDE inhibitors. Compds. of formula I and II wherein R1 is H and halo; R2 is H, halo, (un)substituted cycloalkyl, (un)substituted benzoyl, etc.; Z is O, and (CH2)1-3-O; X is a bond, O, NH, and amino acid residue; R4 is Oh, NO, NO2, amino acid residue, fibric acid residue, guanidine, tetrazolyl, agmatine, etc.; R5 is a statin residue; are claimed. Example compound III was prepared by a general procedure. The invention compds. were evaluated for their ability to treat lipid related disorders.

IT 1094098-94-8P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of compds. for treatment, prevention and combination therapy of lipid-related disorders)

RN 1094098-94-8 CAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.




L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696641 CAPLUS
DOCUMENT NUMBER: 143:172689
TITLE: Preparation of resveratrol ester analogs as sirtuin activators
INVENTOR(S): Andrus, Merritt B.; Liu, Jing
PATENT ASSIGNEE(S): Brigham Young University Technology Transfer Office, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005069998 | A2 | 20050804 | WO 2005-US2229 | 20050119 |
| WO 2005069998 | A3 | 20060105 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005207029 | A1 | 20050804 | AU 2005-207029 | 20050119 |
| CA 2593576 | A1 | 20060804 | CA 2005-2593576 | 20050119 |
| EP 1753708 | A2 | 20070221 | EP 2005-711939 | 20050119 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |

US 20080255382 A1 20081016 US 2006-597335 20060721
PRIORITY APPLN. INFO.: US 2004-537622P P 20040120
US 2004-616537P P 20041006
WO 2005-US2229 W 20050119
OTHER SOURCE(S): CASREACT 143:172689; MARPAT 143:172689
GI




I

AB Resveratrol and ester analogs of formula I [A1-A3 = protecting group, acyl] are prepared The compds. are made from a multi-step process including a N-heterocyclic carbene-type ligand coupling in the presence of a base with benzoyl halide and styrene coupling partners. These compds. show increased stability for use in the food, cosmetic and pharmaceutical industries (no data). Thus, resveratrol (I; A1-A3 = H) was prepared by decarbonylative Heck coupling of 3,5-diacetoxybenzoyl chloride using Pd(OAc)2 and 1,3-bis(2,6-diisopropylphenyl)imidazolinium chloride and 3-acetoxystyrene followed by deprotection with NaOH.

IT 861446-31-3P 861446-36-8P 861446-41-5P
861446-46-0P 861446-51-7P 861446-56-2P
861446-61-9P 861446-66-4P 861446-71-1P
861446-76-6P 861446-81-3P 861446-86-8P
861446-91-5P 861446-96-0P 861447-01-0P
861447-06-5P
RL: COS (Cosmetic use); FFD (Food or feed use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of resveratrol ester analogs as sirtuin activators)

RN 861446-31-3 CAPLUS
CN 1,3-Benzenediol, 5-[2-[4-(1-oxopropoxy)phenyl]ethenyl]- (CA INDEX NAME)




RN 861446-36-8 CAPLUS
CN Butanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-41-5 CAPLUS
CN Pentanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-46-0 CAPLUS
CN Hexanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-51-7 CAPLUS
CN 2,4-Hexadienoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-56-2 CAPLUS
CN Dodecanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-61-9 CAPLUS
CN Hexadecanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-66-4 CAPLUS
CN Octadecanoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)



RN 861446-71-1 CAPLUS
CN 9-Octadecenoic acid (9Z)-, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 861446-76-6 CAPLUS
CN 9,12-Octadecadienoic acid (9Z,12Z)-, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B


RN 861446-81-3 CAPLUS
CN 6,9,12-Octadecatrienoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


RN 861446-86-8 CAPLUS
CN 9,12,15-Octadecatrienoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 861446-91-5 CAPLUS
CN 3,6,9-Octadecatrienoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 861446-96-0 CAPLUS
CN 5,8,11,14-Eicosatetraenoic acid, 4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—$CH_2$—CH═CH—$CH_2$—CH═CH—$(CH_2)_4$—Me

RN 861447-01-0 CAPLUS
CN 5,8,11,14,17-Eicosapentaenoic acid,
4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—$CH_2$—CH═CH—$CH_2$—CH═CH—$CH_2$—CH═CH—Et

RN 861447-06-5 CAPLUS
CN 4,7,10,13,16,19-Docosahexaenoic acid,
4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—$CH_2$—CH═CH—$CH_2$—CH═CH—$CH_2$—CH═CH—$CH_2$—CH═CH—Et

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 12.28 | 199.84 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -1.64 | -1.64 |

STN INTERNATIONAL LOGOFF AT 16:22:11 ON 20 AUG 2009